Clinical Trials

Vopec Pharmaceuticals and Agastiya Biotech announce results from the Phase 1 study of AB001, an investigational small molecule PDL1 immunotherapy for patients with metastasized and locally advanced solid tumors.  Unlike current standard-of-care immuno- and chemotherapy drugs AB001’s novel immunotherapy mechanism of action selectively destroys tumors without harming healthy cells.  Read more on the breakthrough toxicity and efficacy of AB001 on multiple metastatic cancers.